AU2022337284A1 - Methods for the prevention and treatment of synucleinopathies - Google Patents

Methods for the prevention and treatment of synucleinopathies Download PDF

Info

Publication number
AU2022337284A1
AU2022337284A1 AU2022337284A AU2022337284A AU2022337284A1 AU 2022337284 A1 AU2022337284 A1 AU 2022337284A1 AU 2022337284 A AU2022337284 A AU 2022337284A AU 2022337284 A AU2022337284 A AU 2022337284A AU 2022337284 A1 AU2022337284 A1 AU 2022337284A1
Authority
AU
Australia
Prior art keywords
syn
lys
seq
subject
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022337284A
Other languages
English (en)
Inventor
Jean-Cosme DODART
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxxinity Inc
Original Assignee
Vaxxinity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxxinity Inc filed Critical Vaxxinity Inc
Publication of AU2022337284A1 publication Critical patent/AU2022337284A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022337284A 2021-09-01 2022-09-01 Methods for the prevention and treatment of synucleinopathies Pending AU2022337284A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163239505P 2021-09-01 2021-09-01
US63/239,505 2021-09-01
PCT/US2022/075836 WO2023034914A2 (en) 2021-09-01 2022-09-01 Methods for the prevention and treatment of synucleinopathies

Publications (1)

Publication Number Publication Date
AU2022337284A1 true AU2022337284A1 (en) 2024-03-21

Family

ID=85413127

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022337284A Pending AU2022337284A1 (en) 2021-09-01 2022-09-01 Methods for the prevention and treatment of synucleinopathies

Country Status (10)

Country Link
US (1) US20240358806A1 (https=)
EP (1) EP4395894A4 (https=)
JP (1) JP2024534901A (https=)
KR (1) KR20240055785A (https=)
CN (1) CN118119403A (https=)
AU (1) AU2022337284A1 (https=)
CA (1) CA3230300A1 (https=)
MX (1) MX2024002684A (https=)
TW (1) TW202323275A (https=)
WO (1) WO2023034914A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137102A1 (en) * 2023-12-18 2025-06-26 Vaxxinity, Inc. Peptide immunogen compositions and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
EP1572894B1 (en) * 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
EP3638298A4 (en) * 2017-06-16 2021-05-05 United Neuroscience PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN-PROTEIN AND FORMULATIONS THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHIA

Also Published As

Publication number Publication date
US20240358806A1 (en) 2024-10-31
TW202323275A (zh) 2023-06-16
WO2023034914A2 (en) 2023-03-09
CN118119403A (zh) 2024-05-31
MX2024002684A (es) 2024-05-16
EP4395894A2 (en) 2024-07-10
JP2024534901A (ja) 2024-09-26
EP4395894A4 (en) 2025-08-06
CA3230300A1 (en) 2023-03-09
KR20240055785A (ko) 2024-04-29
WO2023034914A3 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
US9102752B2 (en) Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
JP5736565B2 (ja) Ｓｙｎｕｃｌｅｉｎ病の予防および治療
JP5558834B2 (ja) シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
ES2705586T3 (es) Prevención y tratamiento de enfermedades sinucleinopática y amiloidogénica
US20150232524A1 (en) Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
JP2011522842A (ja) パーキンソン病に関連する症状の治療のための化合物
BRPI0706818A2 (pt) composições, métodos e usos de imunogênicos antiamilóides
JP2021508673A (ja) タウペプチド免疫原構築物
ES2727407T3 (es) Prevención y tratamiento de enfermedad sinucleinopática y amiloidogénica
CN1504240A (zh) 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途
US20240358806A1 (en) Methods for the prevention and treatment of synucleinopathies
CN116261464A (zh) 免疫原性化合物
JP2026505017A (ja) タウ及びアミロイドベータペプチド免疫原組成物及び関連方法
JP2023519104A (ja) 凝集膵島アミロイドポリペプチド（ｉａｐｐ）と関連する障害を予防及び治療するための、ｉａｐｐを標的とするペプチド免疫原
US20150165005A1 (en) Method for Treating Amyloid Disease
US20220023401A1 (en) Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type
AU2023307073A1 (en) Tau peptide immunogen constructs
JP2022059682A (ja) Ｃｔｇｆ由来ペプチドおよびその使用